Literature DB >> 17413692

Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda.

David Moore1, Cheryl Liechty, Paul Ekwaru, Willy Were, Gerald Mwima, Peter Solberg, George Rutherford, Jonathan Mermin.   

Abstract

BACKGROUND: Tuberculosis (TB) is the leading cause of death among people with HIV in sub-Saharan Africa. Expanding access to antiretroviral therapy (ART) may reduce the burden of TB, but to what extent is unknown.
METHODS: In a study of 1044 adults who initiated home-based ART in Tororo, Uganda between 1 May 2003 and 30 June 2005, participants were screened for active TB at baseline and then monitored at weekly home visits. Participants with TB at baseline or follow-up were compared with those without TB to determine factors associated with mortality in those with TB.
RESULTS: At baseline, 75 (7.2%) subjects had TB and a total of 53 (5.5%) were diagnosed with TB over a median of 1.4 years of follow-up (3.90 cases/100 person years). Cumulative mortality was 17.9/100 person-years for those with TB and 3.8/100 person-years for those without TB (P < 0.001). Mortality was associated with low baseline CD4 cell counts [relative hazard (RH), 0.99 per 1 cell/microl increase; P = 0.03] and marginally associated with a body mass index <or= 18 (RH, 2.04; P = 0.10) and increasing age (RH, 1.04 per year; P = 0.11). TB incidence and TB-associated mortality were highest within the first 6 months of ART and declined to 52% and 61% of expected values, respectively, from months 7 to 18 after ART initiation.
CONCLUSION: TB remains an important cause of illness and death in patients receiving ART in Uganda. However, both appear to decline markedly, after 6 months of ART.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17413692     DOI: 10.1097/QAD.0b013e328013f632

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  101 in total

1.  Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies.

Authors:  Annelies Van Rie; Daniel Westreich; Ian Sanne
Journal:  J Acquir Immune Defic Syndr       Date:  2011-04       Impact factor: 3.731

2.  Supporting southern-led research: implications for North-South research partnerships.

Authors:  Katherine A Muldoon; Josephine Birungi; Nicole S Berry; Moses H Ngolobe; Robert Mwesigwa; Kate Shannon; David M Moore
Journal:  Can J Public Health       Date:  2012 Mar-Apr

3.  Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART increase the short-term TB risk in a low incidence TB setting?

Authors:  April C Pettit; Cathy A Jenkins; Samuel E Stinnette; Peter F Rebeiro; Robert B Blackwell; Stephen P Raffanti; Bryan E Shepherd; Timothy R Sterling
Journal:  J Acquir Immune Defic Syndr       Date:  2011-08-01       Impact factor: 3.731

4.  High diagnostic yield of tuberculosis from screening urine samples from HIV-infected patients with advanced immunodeficiency using the Xpert MTB/RIF assay.

Authors:  Stephen D Lawn; Andrew D Kerkhoff; Monica Vogt; Robin Wood
Journal:  J Acquir Immune Defic Syndr       Date:  2012-07-01       Impact factor: 3.731

5.  Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it?

Authors:  S D Lawn; A D Harries; B G Williams; R E Chaisson; E Losina; K M De Cock; R Wood
Journal:  Int J Tuberc Lung Dis       Date:  2011-05       Impact factor: 2.373

6.  Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.

Authors:  François-Xavier Blanc; Thim Sok; Didier Laureillard; Laurence Borand; Claire Rekacewicz; Eric Nerrienet; Yoann Madec; Olivier Marcy; Sarin Chan; Narom Prak; Chindamony Kim; Khemarin Kim Lak; Chanroeurn Hak; Bunnet Dim; Chhun Im Sin; Sath Sun; Bertrand Guillard; Borann Sar; Sirenda Vong; Marcelo Fernandez; Lawrence Fox; Jean-François Delfraissy; Anne E Goldfeld
Journal:  N Engl J Med       Date:  2011-10-20       Impact factor: 91.245

7.  Implementation and operational research: Integrated pre-antiretroviral therapy screening and treatment for tuberculosis and cryptococcal antigenemia.

Authors:  Lincoln Pac; Mara Murray Horwitz; Anne Marion Namutebi; Brandon J Auerbach; Aggrey Semeere; Teddy Namulema; Miriam Schwarz; Robert Bbosa; Allan Muruta; David B Meya; Yukari C Manabe
Journal:  J Acquir Immune Defic Syndr       Date:  2015-04-15       Impact factor: 3.731

8.  Reducing the burden of tuberculosis presenting during the initial months of antiretroviral therapy in resource-limited settings.

Authors:  Stephen D Lawn; David J Edwards; Robin Wood
Journal:  Clin Infect Dis       Date:  2010-01-01       Impact factor: 9.079

9.  Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV.

Authors:  R Dawson; P Masuka; D J Edwards; E D Bateman; L-G Bekker; R Wood; S D Lawn
Journal:  Int J Tuberc Lung Dis       Date:  2010-01       Impact factor: 2.373

10.  Early mortality and cause of deaths in patients using HAART in Brazil and the United States.

Authors:  Beatriz Grinsztejn; Valdilea G Veloso; Ruth K Friedman; Ronaldo I Moreira; Paula M Luz; Dayse P Campos; José H Pilotto; Sandra W Cardoso; Jeanne C Keruly; Richard D Moore
Journal:  AIDS       Date:  2009-10-23       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.